Global Remdesivir Market Size, Share, and Trends Analysis Report, By Dosage (2.5 Mg, 5Mg, 100Mg, and 200 Mg), By Form (Lyophilized Powder and Concentrated Solution), By Application (Ebola, SARS-COV, MERS-COV, and COVID-19), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Forecast (2022-2028)

The global remdesivir market is anticipated to grow at a CAGR of 6.0% during the forecast period (2022- 2028). Remdesivir (RDV) is one of the promising drugs for the treatment of the COVID-19 disease. The FDA has approved an Emergency Use Authorization to allow adults and children who are hospitalized with severe COVID-19 to receive Remdesivir.  Remdesivir is a broad spectrum anti-viral medication which was firstly developed by Gilead Sciences. It is administered through injection into the vein. Remdesivir is a prodrug of nucleotide. Originally remdesiver is used in the treatment of hepatitis C, Ebola virus, and Marburg virus infection.

With the rise in cases of viral infections, the surge in unhygienic practices in rural areas, the increase in demand to overcome viral infections, the surge in cases of COVID-19 across the globe, the increase in geriatric population, and the rise in hospital-acquired infections are the some of the key factors that drive the growth of the remdesivir market. However, the shortage of remdesivir supply and availability of substitutes can restrain the growth of the market. The market is segmented based on the dosage, form, application, and distribution channel. Based on the form, the market is sub-segmented into lyophilized powder and concentrated solution. The lyophilized powder is a freeze-dried powder. This is a peptide in the form of lyophilized powder. A concentrated solution is one that has a relatively large amount of dissolved solute. It has a small amount of dissolved solute in it.

Some major players in the market include Cipla Ltd., Mylan NV, and Zydus Healthcare Ltd., among others.  The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships, new product launches, and collaborations, to stay competitive in the market. For instance, in 2020, Jubilant Pharma Ltd announced the launch of Remdesivir for injection 100mg vial under the brand name JUBI-R. This injection can be used in the treatment of COVID-19. Additionally, in 2020, Mylan NV announced the commercial launch of Remdesivir for injection under the brand name DESREMTM in India. This is a licensed drug for the treatment of COVID-19 patients. In 2020, Zydus Group announced the launch of Remdesivir lyophilized injection 100mg/vial. This injection can be used for patients suffering from SARS-CoV2.

Market Coverage                            

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Dosage
  • By Form
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Cipla Ltd., Mylan NV, and Zydus Healthcare Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?

Global Remdesivir Market Report by Segment

By Dosage

• 5 Mg
• 5 Mg
• 100 Mg
• 200 Mg

By Form

• Lyophilized Powder
• Concentrated Solution

By Application

• Ebola
• SARS-COV
• MERS-COV
• COVID-19

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Remdesivir Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa